Beeline Medicines' afimetoran, acquired from Bristol Myers Squibb, showed better lupus response rates vs placebo in all dose groups, spurring plans for a pivotal trial.
The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The company, which was built by Bain Capital, has now raised more than $426 million in its quest to advance a portfolio of…
Bain Capital, the Canada Pension Plan Investment Board, and Bristol Myers are doubling down on Beeline Medicines with a $126.3…
BeOne's Brukinsa plus rituximab cut disease progression risk by 43% versus chemoimmunotherapy in a Phase 3 frontline mantle cell…
A Brukinsa regimen has delivered a large progression-free survival (PFS) benefit in what BeOne Medicines called a “new…
Pfizer's Litfulo wins Phase 3 for vitiligo; Braveheart Bio eyes $275M IPO testing Hengrui drug; Attovia targets $182M IPO; Pfizer…
Two months after UCB revealed the success of Bimzelx in a head-to-head trial aga | Two months after UCB revealed the success of…
